Hodgkin's disease (Hodgkin's lymphoma)

From Aaushi
Jump to navigation Jump to search

Classification

  • not a true lymphoma
  • malignant cells are not of lymphocytic origin
Histology prevalence prognosis
lymphocyte predominance 2-10% excellent
nodular sclerosis 40-80% very good
mixed cellularity 20-40% good
lymphocyte depletion 2-15% poor

Etiology

Epidemiology

  • seasonal variation in incidence & mortality

Pathology

Genetics

Clinical manifestations

Laboratory

Diagnostic procedures

Radiology

Staging

Complications

* chemotherapy does not increase risk of breast cancer[3]

Differential diagnosis

Management

* chemotherapy does not increase risk of breast cancer[3]

More general terms

More specific terms

Additional terms

References

  1. Harrison's Principles of Internal Medicine, 13th ed. Isselbacher et al (eds), McGraw-Hill Inc. NY, 1994, pg 1782, 1786
  2. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 423-26
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 539
  5. 5.0 5.1 Ferri's Clinical Advisor, Instant Diagnosis and Treatment, Ferri FF (ed), Mosby, Philadelphia, 2003
  6. 6.0 6.1 Steidl C, Lee T, Shah SP et al Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010 Mar 11; 362:875. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20220182 Free PMC Article <Internet> http://content.nejm.org/cgi/content/full/362/10/875
  7. 7.0 7.1 Engert A et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010 Aug 12; 363:640. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20818855
  8. 8.0 8.1 Kostakoglu L, Coleman M, Leonard JP et al PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002 Aug;43(8):1018-27. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12163626
  9. 9.0 9.1 Ferme C, Eghbali H, Meerwaldt JH et al Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 Nov 8;357(19):1916-27. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17989384
  10. Gallamini A, Hutchings M, Rigacci L et al Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17646666
  11. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998 Nov 19;339(21):1506-14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/9819449
  12. Adams MJ, Lipsitz SR, Colan SD et al Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004 Aug 1;22(15):3139-48. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15284266
  13. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011 Jul;154(1):23-31 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21539537
  14. 14.0 14.1 14.2 Anello J, Feinberg B, Heinegg J, Lindsey R, Wojdylo C, Wong O. Medcsape Oncology. August 2014 Guidelines for Hodgkin lymphoma from British Committee for Standards in Haematology http://reference.medscape.com/features/slideshow/guidelines-review/august2014
  15. 15.0 15.1 15.2 van Nimwegen FA et al Cardiovascular Disease After Hodgkin Lymphoma Treatment. 40-Year Disease Risk. JAMA Intern Med. Published online April 27, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25915855 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=2278950
    Tonorezos E, Overholser L Caring for the Adult Survivor of Hodgkin Lymphoma. Highlighting the Need for Care Coordination. JAMA Intern Med. Published online April 27, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25915209 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=2278946
  16. 16.0 16.1 Kostakoglu L, Goldsmith SJ, Leonard JP et al FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006 Dec 1;107(11):2678-87 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17063502
  17. 17.0 17.1 Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013 Jun 20;6:CD009411 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23784872
  18. 18.0 18.1 Swerdlow AJ, Cooke R, Bates A et al Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol. 2012 Aug 1;30(22):2745-52 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22734026
  19. 19.0 19.1 19.2 19.3 19.4 19.5 19.6 Schaapveld M, Aleman BM, van Eggermond AM et al Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015 Dec 24;373(26):2499-511 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26699166
    Radford J, Longo DL. Second Cancers after Treatment for Hodgkin's Lymphoma - Continuing Cause for Concern. N Engl J Med. 2015 Dec 24;373(26):2572-3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26699173
  20. 20.0 20.1 Connors JM, Jurczak W, Straus DJ et al Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. Dec 10, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29224502 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1708984
    Longo DL, DeVita DT Jr. Progress in the Treatment of Hodgkin's Lymphoma. N Engl J Med. Dec 10, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29224505 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1715141
  21. Hoppe RT, Advani RH, AI WZ, et al. NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29523663 <Internet> http://www.jnccn.org/content/16/3/245.long
  22. 22.0 22.1 22.2 Minerd J. Expert critique by Taylor J Hodgkin Lymphoma Risk: 'Intriguing' Early Links Suggestive of Season Patterns, Role for Vitamin D Relates to biological evidence that vitamin D enhances antibody-dependent cellular cytotoxicity by rituximab. MedPage Today. ASCO Reading Room 06.06.2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/73311
    Borchmann S, Muller H, Engert A. Hodgkin lymphoma has a seasonal pattern of incidence and mortality that depends on latitude. Sci Rep. 2017 Nov 2;7(1):14903. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29097683 Free PMC Article
  23. 23.0 23.1 23.2 23.3 23.4 23.5 23.6 23.7 Eichenauer Da, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. May 23, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29796651 https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy080/4999396
  24. Ansell SM. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc. 2015 Nov;90(11):1574-83. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26541251
  25. 25.0 25.1 Deng J et al. Risk of hematologic cancer in patient with undifferentiated pruritis. JAMA Dermatol 2022 Jul; 158:791. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35612839 PMCID: PMC9134041 (available on 2023-05-25) https://jamanetwork.com/journals/jamadermatology/fullarticle/2792454

Patient information

Hodgkin's disease patient information